8-K: Amylyx Pharmaceuticals Reports Q1 2024 Results, Focuses on Pipeline After Drug Discontinuation

Amylyx Pharmaceuticals reported its first quarter 2024 financial results, announced the discontinuation of RELYVRIO/ALBRIOZA, and highlighted progress in its clinical pipeline.

Summary

• Amylyx Pharmaceuticals announced its financial results for the first quarter of 2024, reporting a net product revenue of $88.6 million, compared to $71.4 million in the same period of 2023.
• The company experienced a net loss of $118.8 million, or $1.75 per share, compared to a net income of $1.6 million, or $0.02 per share, in the first quarter of 2023.
• This loss was primarily due to a $110.5 million non-cash charge related to the write-down of inventory and loss on firm purchase commitments following the decision to discontinue RELYVRIO/ALBRIOZA.
• Amylyx is discontinuing the marketing authorizations for RELYVRIO/ALBRIOZA in the U.S. and Canada based on topline results from the Phase 3 PHOENIX trial.
• The company is focusing its resources on key clinical programs, including AMX0035 for Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 for ALS.
• Interim data from the Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome showed improvements in pancreatic function, glycemic control, and vision in eight participants.
• Topline data from all 12 participants in the HELIOS trial is expected in the fall of 2024.
• An interim analysis from the ORION study of AMX0035 in PSP is expected in mid-2025.
• Amylyx plans to initiate a clinical trial of AMX0114 in ALS in the second half of 2024.
• The company's cash, cash equivalents, and short-term investments totaled $373.3 million as of March 31, 2024, providing an expected cash runway into 2026.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the significant net loss and the discontinuation of a key product. However, the company's focus on its pipeline and strong cash position provide some positive aspects.

Positives

• Net product revenue increased to $88.6 million in Q1 2024 compared to $71.4 million in Q1 2023.
• Interim data from the HELIOS trial showed encouraging improvements in Wolfram syndrome patients.
• The company has a strong cash position of $373.3 million, providing a cash runway into 2026.
• Amylyx is advancing its pipeline with planned trials for AMX0035 in Wolfram syndrome and PSP, and AMX0114 in ALS.
• The company is focusing resources on key clinical programs after discontinuing RELYVRIO/ALBRIOZA.

Negatives

• Amylyx reported a significant net loss of $118.8 million in Q1 2024.
• The company is discontinuing the marketing authorizations for RELYVRIO/ALBRIOZA, resulting in a $110.5 million non-cash charge.
• Cost of sales increased significantly to $116.4 million in Q1 2024, compared to $5.3 million in Q1 2023.
• Research and development expenses increased to $36.6 million in Q1 2024, compared to $24.2 million in Q1 2023.
• Selling, general, and administrative expenses increased to $57.8 million in Q1 2024, compared to $44.0 million in Q1 2023.

Risks

• The discontinuation of RELYVRIO/ALBRIOZA will impact revenue and requires a significant write-down of inventory.
• Clinical trial results may not be positive, and regulatory approvals are not guaranteed.
• The company's financial performance is subject to risks and uncertainties, including the success of its program development activities.
• Global macroeconomic uncertainty, geopolitical instability, and public health events could impact Amylyx's operations.
• The company's ability to fund operations is a risk.

Future Outlook

Amylyx expects its current cash position to provide a runway into 2026, allowing the company to focus on key upcoming milestones, including data readouts from the HELIOS and ORION trials, and the planned trial of AMX0114 in ALS. The company is also focused on diseases with high unmet needs and well-defined biomarkers.

Management Comments

• We are focused on diseases where there is a high unmet need for better therapies and where there are well-defined measurable biomarkers, rigorous supporting preclinical data, and well-defined rationales for our therapy's mechanism of action, said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx.
• We anticipate multiple near-term catalysts for our pipeline, including data from our ongoing clinical trials of AMX0035 in Wolfram syndrome this fall and PSP in mid-2025.

Industry Context

The discontinuation of RELYVRIO/ALBRIOZA highlights the challenges in developing effective treatments for neurodegenerative diseases. The company's focus on new clinical programs reflects a broader industry trend towards targeted therapies for specific patient populations with high unmet needs. The company's focus on diseases with well-defined biomarkers is also a common strategy in the industry.

Comparison to Industry Standards

• The decision to discontinue RELYVRIO/ALBRIOZA after a Phase 3 trial failure is not uncommon in the pharmaceutical industry, where clinical trial setbacks are a regular occurrence.
• The focus on rare diseases like Wolfram syndrome and PSP aligns with a trend in the industry to pursue niche markets with limited treatment options, similar to companies like BioMarin and Sarepta Therapeutics.
• The development of AMX0114, an antisense oligonucleotide, is in line with the industry's growing interest in gene-based therapies, as seen with companies like Ionis Pharmaceuticals and Alnylam Pharmaceuticals.
• The company's cash runway into 2026 is a positive sign, but it will need to manage its expenses carefully, similar to other biotech companies in the development stage.
• The increase in R&D expenses is typical for a company advancing multiple clinical programs, and is comparable to other companies in the biotech sector.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the net loss and the discontinuation of RELYVRIO/ALBRIOZA.
• Employees may be affected by the restructuring and focus on key programs.
• Patients with ALS in the US and Canada will no longer have access to RELYVRIO/ALBRIOZA, but those currently on the drug can transition to a free drug program.
• Patients with Wolfram syndrome and PSP may benefit from the ongoing clinical trials of AMX0035.
• The company's suppliers and creditors may be impacted by the changes in the company's product portfolio.

Next Steps

• Amylyx plans to engage with the FDA based on interim data from the Phase 2 HELIOS clinical trial.
• The company anticipates reporting topline data from all 12 participants in the HELIOS trial in the fall of 2024.
• Amylyx expects an interim analysis from the ORION study in mid-2025.
• The company plans to initiate a clinical trial of AMX0114 in ALS in the second half of 2024.

Key Dates

Keywords

Amylyx Pharmaceuticals, AMX0035, AMX0114, RELYVRIO, ALBRIOZA, Wolfram syndrome, Progressive supranuclear palsy, ALS, Clinical trials, Neurodegenerative diseases, Financial results, Drug development